China Resources Pharmaceutical Group Ltd. (HK:3320)
:3320
Want to see HK:3320 full AI Analyst Report?
Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
Select Model
Select Model
Rating:58Neutral
Price Target:
HK$5.50
â–²(19.31% Upside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by steady but low-margin financial performance and rising leverage risk, partially offset by solid cash generation. Technicals are a meaningful drag due to weak near-term momentum and price below the 20-day average. Valuation supports the stock with a low P/E and a moderate dividend yield.
Positive Factors
Steady revenue growth
The company has delivered steady, mid-single-digit top-line expansion with modest gross-margin improvement into 2025. Persistent revenue growth across distribution, retail and manufacturing supports scale economics, preserves market share, and underpins long-term organic cash generation.
Negative Factors
Rising leverage
Leverage has risen materially through 2025 (debt-to-equity ~1.83), increasing financial risk. Higher debt constrains strategic optionality, raises refinancing and interest-rate sensitivity, and reduces the firm's buffer against revenue or margin shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
The company has delivered steady, mid-single-digit top-line expansion with modest gross-margin improvement into 2025. Persistent revenue growth across distribution, retail and manufacturing supports scale economics, preserves market share, and underpins long-term organic cash generation.
Read all positive factors
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$30.16B
Dividend Yield2.95%
Average Volume (3M)13.76M
Price to Earnings (P/E)6.2
Beta (1Y)0.77
Revenue Growth4.66%
EPS Growth20.76%
CountryHK
Employees72,700
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.74Price Target Upside46.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The compan...
How the Company Makes Money
The company makes money primarily by selling pharmaceuticals and healthcare-related products through three main business lines: (1) Pharmaceutical distribution: it generates revenue by purchasing medicines and healthcare products from manufacturer...
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
52
Neutral
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 300.01B | 274.18B | 270.40B | 254.11B | 236.81B |
| Gross Profit | 49.53B | 43.30B | 42.18B | 39.13B | 35.38B |
| EBITDA | 17.70B | 15.45B | 15.43B | 15.47B | 11.95B |
| Net Income | 4.50B | 3.57B | 3.85B | 3.50B | 3.08B |
Balance Sheet | |||||
| Total Assets | 318.34B | 274.28B | 271.48B | 243.93B | 248.56B |
| Cash, Cash Equivalents and Short-Term Investments | 58.73B | 17.48B | 59.27B | 32.52B | 37.32B |
| Total Debt | 104.87B | 73.43B | 62.16B | 63.85B | 67.96B |
| Total Liabilities | 187.52B | 169.90B | 169.20B | 150.24B | 152.69B |
| Stockholders Equity | 57.26B | 51.34B | 50.60B | 49.56B | 50.98B |
Cash Flow | |||||
| Free Cash Flow | 16.93B | 14.55B | 12.42B | 7.54B | 8.32B |
| Operating Cash Flow | 20.48B | 17.55B | 15.55B | 10.90B | 11.22B |
| Investing Cash Flow | -10.07B | -8.89B | -2.07B | -3.30B | -8.83B |
| Financing Cash Flow | -10.96B | -16.84B | -4.07B | -9.00B | 5.31B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
Negative
4.61
Price Trends
5.33
Negative
4.95
Negative
4.93
Negative
Market Momentum
-0.19
Positive
30.05
Neutral
7.27
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3320, the sentiment is Negative. The current price of 4.61 is below the 20-day moving average (MA) of 5.22, below the 50-day MA of 5.33, and below the 200-day MA of 4.93, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 30.05 is Neutral, neither overbought nor oversold. The STOCH value of 7.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3320.
China Resources Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$29.40B | 9.36 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$27.20B | 18.83 | 8.60% | 2.26% | 10.00% | -7.54% | |
58 Neutral | HK$30.16B | 6.21 | 7.98% | 2.95% | 4.66% | 20.76% | |
58 Neutral | HK$68.27B | 13.21 | 7.19% | 1.69% | 1.52% | 22.54% | |
57 Neutral | HK$19.81B | 22.15 | 7.26% | 3.13% | 5.48% | -49.67% | |
56 Neutral | HK$38.86B | 3.39 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3320
China Resources Pharmaceutical Group Ltd.
4.80
-0.18
-3.67%
HK:0867
China Medical System Holdings
11.15
2.57
29.91%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
16.07
-0.66
-3.93%
HK:1513
Livzon Pharmaceutical Group
27.66
1.46
5.56%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.66
3.46
24.35%
HK:0512
Grand Pharmaceutical Group Limited
5.58
-2.87
-33.96%
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharma Discloses Subsidiary’s Unaudited Q1 2026 Results Linked to PRC Note Issuance
Apr 30, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, has published unaudited financial statements for the three months ended 31 March 2026...
China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China
Apr 28, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Company Limited, has completed the public issuance of the second tranche of its 2026 corporate bonds i...
China Resources Pharmaceutical Discloses Weaker Q1 2026 Unaudited Results at Boya Bio-Pharmaceutical
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed unaudited first-quarter 2026 figures for its Shenzhen-listed subsidiary, China Resources Boya Bio-pharmaceutical, which it controls with around 41.79% of the voting rights. The announcement highli...
CR Pharmaceutical Subsidiary CR Sanjiu Posts Higher Q1 Revenue but Weaker Cash Flow
Apr 24, 2026
China Resources Pharmaceutical Group has reported the unaudited first-quarter 2026 financial performance of its 63.22%-owned subsidiary, China Resources Sanjiu Medical Pharmaceutical. CR Sanjiu posted revenue of RMB 8.13 billion, up from RMB 6.85...
China Resources Pharma Flagship KPC Swings to Q1 Loss on Slumping Revenue
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its subsidiary KPC Pharmaceuticals, which showed a sharp deterioration in performance. KPC’s revenue fell to RMB836.2 million from RMB1....
CR Double-Crane Posts Softer Q1 Earnings but Stronger Cash Position for 2026
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the unaudited first-quarter 2026 financial results of its Shanghai-listed subsidiary, China Resources Double-Crane, which remain subject to potential audit adjustments and do not represent the con...
CR Jiangzhong Q1 2026 Profit Rises on Strong Cash Flow Despite Revenue Dip
Apr 24, 2026
China Resources Jiangzhong Pharmaceutical Co., Ltd., a Shanghai-listed subsidiary effectively controlled by China Resources Pharmaceutical Group Ltd., reported unaudited first-quarter 2026 results prepared under PRC GAAP. The company remains well-...
China Resources Pharma Flags Higher Q1 Profit at Tasly but Warns on Cash Outflow and Limited Scope
Apr 24, 2026
China Resources Pharmaceutical has disclosed key first‑quarter 2026 figures from subsidiary Tasly Pharmaceutical, which reported unaudited revenue of RMB2.16 billion and net profit of RMB364.6 million, both higher than a year earlier. Tasly&...
China Resources Pharma Highlights Strong First-Quarter Performance at Dong-E-E-Jiao
Apr 24, 2026
China Resources Pharmaceutical Group has disclosed the latest unaudited quarterly figures of its controlled subsidiary Dong-E-E-Jiao, a Shenzhen-listed Chinese medicine producer, highlighting the unit’s growing scale and strong balance sheet...
China Resources Pharmaceutical Raises RMB1.5 Billion in First Tranche of 2026 Bonds
Apr 16, 2026
China Resources Pharmaceutical Group Limited has announced that its wholly owned subsidiary China Resources Pharmaceutical Holdings Company Limited has completed the public issuance of the first tranche of its 2026 corporate bonds in mainland Chin...
China Resources Pharmaceutical Completes First Tranche of 2026 PRC Bond Issuance
Mar 27, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the issuance of the first tranche of its 2026 corporate bonds in mainland China. The bo...
China Resources Pharma Subsidiary Raises Up to RMB1 Billion in 2026 Bond Issue
Mar 26, 2026
China Resources Pharmaceutical Group has announced that its non-wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical, has completed the first tranche issuance of its 2026 corporate bonds in mainland China to qualified investors. Th...
China Resources Pharmaceutical Delivers Higher Revenue and Profit in 2025
Mar 24, 2026
China Resources Pharmaceutical Group reported audited consolidated revenue of RMB269.57 billion for 2025, up from RMB257.67 billion a year earlier, with gross profit rising to RMB44.51 billion as it continued to scale its pharmaceutical manufactur...
China Resources Pharmaceutical Declares Final 2025 Dividend With Currency Option
Mar 24, 2026
China Resources Pharmaceutical Group Limited has declared a final ordinary dividend of RMB 0.122 per share for the financial year ended 31 December 2025, subject to shareholder approval on 29 May 2026. The dividend will be payable in Hong Kong dol...
CR Sanjiu Posts Strong Asset and Revenue Growth, Boosts Dividend for 2025
Mar 20, 2026
China Resources Sanjiu Medical Pharmaceutical Company Limited, a Shenzhen-listed subsidiary 63.22% owned by China Resources Pharmaceutical Group, reported strong balance sheet growth for 2025, with total assets rising 46.71% to about RMB58.8 bill...
CR Boya Revenue Rises but Profit Slumps as China Resources Pharma Unit Proposes Dividend
Mar 20, 2026
China Resources Pharmaceutical has disclosed key 2025 financial data for its Shenzhen-listed subsidiary China Resources Boya Bio-pharmaceutical, which remains under its control via a 30.48% equity stake and 41.79% voting rights. The unit operates ...
China Resources Pharma Subsidiary Dong-E-E-Jiao Lifts 2025 Profit and Proposes Higher Dividend
Mar 19, 2026
Dong-E-E-Jiao, a key subsidiary of China Resources Pharmaceutical Group, reported modest balance sheet expansion for 2025, with total assets rising 2.18% and net assets attributable to shareholders edging up 0.20%. The company strengthened profita...
China Resources Pharma Subsidiary KPC Posts Profit Slump but Maintains Dividend
Mar 19, 2026
KPC Pharmaceuticals, Inc., a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported audited results for the year ended 31 December 2025 showing total assets of RMB11.77 billion, down 6.64% year on year, while net assets attri...
CR Double-Crane Grows Profit and Net Assets Despite Flat 2025 Revenue
Mar 19, 2026
China Resources Double-Crane Pharmaceutical, a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported modest balance sheet expansion in 2025, with total assets up 1.94% and net assets attributable to shareholders rising 11.78...
CR Jiangzhong Lifts Profit and Dividend Despite Revenue Dip in 2025
Mar 19, 2026
China Resources Jiangzhong Pharmaceutical, a key subsidiary of China Resources Pharmaceutical Group, reported audited total assets of RMB6.88 billion and net assets attributable to shareholders of RMB4.02 billion as of 31 December 2025, up 5.73% a...
China Resources Pharmaceutical Plans Further Stake Sale in Tianmai Biotechnology
Mar 16, 2026
China Resources Pharmaceutical Group has launched a public tender to sell about 5.88% of its equity stake in Tianmai Biotechnology Development Co., Ltd. through the Shanghai United Assets and Equity Exchange, with an initial minimum listing price ...
China Resources Pharmaceutical Sets March Board Meeting on 2025 Results, Dividend Plan
Mar 6, 2026
China Resources Pharmaceutical Group Limited has scheduled a board meeting for 24 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final ...
China Resources Pharma Unit to Invest RMB1.5 Billion in New Health Consumer Products Park
Feb 10, 2026
China Resources Pharmaceutical Group’s subsidiary Dong-E-E-Jiao plans to invest about RMB1.485 billion in a new health consumer products industrial park in Dong-E County Economic Development Zone, Liaocheng, Shandong. The park will span roug...
China Resources Pharma Launches RMB1.42 Billion Tender to Sell Tianmai Biotechnology Stake
Feb 9, 2026
China Resources Pharmaceutical Group has begun a process to sell about 17.87% of its equity stake in Hefei Tianmai Biotechnology Development through a public tender on the Shanghai United Assets and Equity Exchange, with a minimum listing price of...
China Resources Pharmaceutical Shareholders Approve Sales Framework and New Articles at 2026 EGM
Feb 6, 2026
China Resources Pharmaceutical Group Limited announced that all resolutions proposed at its first extraordinary general meeting of 2026, held on 6 February, were duly approved by shareholders by way of poll. The meeting approved the Sales Framewor...
CR Sanjiu Posts Double-Digit Revenue Growth but Softer Profit Gains in 2025
Feb 6, 2026
China Resources Sanjiu Medical Pharmaceutical Co., Ltd., a 63.22%-owned subsidiary of China Resources Pharmaceutical Group Limited, reported unaudited preliminary financial results for 2025 showing solid top-line growth but more modest gains in p...
Tasly Pharmaceutical Posts Higher 2025 Profit Despite Revenue Dip and Reliance on One-Off Gains
Feb 6, 2026
Tasly Pharmaceutical Group Co., Ltd., a consolidated subsidiary of China Resources Pharmaceutical Group, reported unaudited preliminary results for 2025 showing a slight 3.1% decline in total operating revenue to RMB 8.24 billion but notable impro...
Subsidiary KPC Pharmaceuticals Warns of Sharp Profit Decline in 2025 Unaudited Results
Feb 6, 2026
KPC Pharmaceuticals, a Shanghai-listed subsidiary of China Resources Pharmaceutical Group, reported a sharp deterioration in unaudited results for 2025, with total operating revenue falling 21.72% year on year to RMB 6.58 billion and operating pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.